DOI:

SR200 MyoCath™ percutaneous microimplant delivery system

Howard Leonhardt*, Richard Spencer

Description

The SR200 MyoCath™ is a endoventricular needle-injection catheter utilizing catheter tip deflection technology and a adjustable depth, spring-loaded needle to provide multiple and precise delivery of biologic injectate to targeted myocardium.

History

MyoCath™ intellectual property was secured in 1999 and 2000. Initial prototypes were created and design was finalized in 2000. Bench testing, design control testing, biocompatibility/toxicity testing, thrombogenicity testing, in vitro testing and in vivo testing were all completed in 2001. MyoCath™ is manufactured in an ISO certified, class 100,000 controlled environment room and has been in clinical use since 2002.

Technical specifications

Indication for use

MyoCath™ is an investigational device indicated for injecting an aqueous solution or suspension, for diagnostic or therapeutic purposes, into internal tissues or organs.

Tips and tricks for delivery (use)

– Use of a steerable guidewire is not required.

– Slight deflection of the catheter tip facilitates crossing the aortic valve when performing endoventricular injections.

– A 9F guide catheter can be used if additional back-up support is required to reach difficult areas (i.e. septal) of the left ventricle.

– During long procedures, flushing the catheter with cold saline restores torquability and back-up support.

– Using deliberate force to extend the needle and infusing the injectate slowly over several seconds helps to optimize channel creation and injectate retention in scarred areas of myocardium.

– PVCs and tactile feel will confirm presence of the needle against the myocardial wall.

– Mixing injectate with non-ionic contrast enhances visualization of injectate retention under fluoroscopy.

Preclinical experience

As part of the design validation effort, Bioheart, Inc. performed ten in vivo studies in the porcine model to assess performance and ease of use of the MyoCath™ in the hands of a number of experienced interventional cardiologists. The primary objective was to ensure the design is suitable for its intended use under simulated conditions in the animal model. Physicians rated the performance of the device using the following metrics:

– Device preparation

– Ease of access

– Ease of placement

– Needle core advancement / retraction

– Needle insertion / removal

– Device injection

– Device visualization

– Ease of removal

– Thrombogenicity

– Device integrity

– Overall performance

– Standard anticoagulation regime

– Comparison with standard practices

Overall, the physicians rated the MyoCath™ favorably and reported it performed in an acceptable manner.

Clinical experience

The MyoCath™ has been used in 25 clinical cases to-date. All clinical cases involved injections in chronically infracted left ventricles (septal, anterior and posterior locations were targeted). No adverse events related to MyoCath™ have ever been reported, and feedback captured from physicians following completion of these cases was highly positive.

Volume 1 Number 4
Feb 20, 2006
Volume 1 Number 4
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-24-00065 Apr 21, 2025
From invasive gradients to pressure recovery: rethinking long-standing paradigms
Joner M and Mylotte D
free

Editorial

10.4244/EIJ-E-25-00011 Apr 21, 2025
Transcatheter aortic valve implantation with complex, high-risk indicated PCI
Patterson T and McDonaugh B
free

Original Research

10.4244/EIJ-D-24-00341 Apr 21, 2025
Prognostic value of invasive versus echocardiography-derived aortic gradient in patients undergoing TAVI
van den Dorpel M et al

Flashlight

10.4244/EIJ-D-24-00871 Apr 21, 2025
Management of bioprosthetic valve failure at 10 years after TAV-in-SAV
Jelisejevas J et al

Debate

10.4244/EIJ-E-24-00071 Apr 21, 2025
Could the age threshold for TAVI be relaxed to below 65 years? Pros and cons
Garot P et al

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
Trending articles
69.746

10.4244/EIJV13I12A217 Dec 8, 2017
Swimming against the tide: insights from the ORBITA trial
Al-Lamee R and Francis D
free
59.15

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
57.6

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
39.45

Clinical research

10.4244/EIJ-D-23-00725 Nov 19, 2023
A systematic algorithm for large-bore arterial access closure after TAVI: the TAVI-MultiCLOSE study
Rosseel L et al
free
39.45

Original Research

10.4244/EIJ-D-23-00725 Mar 18, 2024
A systematic algorithm for large-bore arterial access closure after TAVI: the TAVI-MultiCLOSE study
Rosseel L et al
free
38.75

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
36

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
35.15

State-of-the-Art

10.4244/EIJ-D-23-00895 Apr 1, 2024
Percutaneous interventions for pulmonary embolism
Finocchiaro S et al
free
28.5

CLINICAL RESEARCH

10.4244/EIJV11I1A6 May 19, 2015
European expert consensus on rotational atherectomy
Barbato E et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved